摘要
背景与目的:丝氨酸蛋白水解酶的uPA(urokinase-typeplasminogenactivator)uPAR(urokinase-typeplasminogenactivatorreceptor)作用系统被认为在细胞外基质和基底膜的降解、促进肿瘤侵袭转移过程中起核心作用,本研究旨在探讨uPA、uPAR在尿路移行细胞癌组织中的表达及其与肿瘤侵袭行为的关系。方法:应用免疫组织化学PicTureTM通用型二步法检测50例肾盂输尿管癌及40例膀胱癌组织中uPA和uPAR的表达水平及分布。结果:uPA和uPAR在正常肾盂、输尿管、膀胱组织中未见表达,在癌组织中的表达明显高于癌旁组织;G1级uPA和uPAR的阳性率分别为33.33%、50.00%,G3级分别为88.47%和96.15%;Ta~T1期的分别为37.50%和50.00%,T4期均为100.0%;在高分级、高分期肿瘤组织中,uPA和uPAR的阳性率明显升高(P<0.05),且uPA阳性与uPAR阳性高度相关(rs=0.979)。结论:uPA、uPAR的共同表达是尿路移行细胞癌的特征之一,且与分级和分期密切相关,在尿路移行细胞癌浸润和转移中可能具有重要作用。
BACKGROUND &OBJECTIVE: Urokinase-type plasminogen activator (uPA)/its receptor (uPAR), serine protease system, plays a key role in the degradatio n of extracellular matrix and basement membranes, and intensifying the tumor inv asion. The study was designed to investigate the expression of uPA and uPAR in u rinary transitional cell carcinoma. The correlation between their expression and tumor invasion was evaluated. METHODS: The expression and localization of uPA a nd uPAR were examined among 50 cases of renal pevic and ureter carcinoma and 40 cases of bladder cancer using the PicTureTM current type of immunohistochemical two-step method. RESULTS: The normal pelvic, ureter, and bladder did not expres s uPA and uPAR. The positive expression of uPA and uPAR were concentrated in tum or tissues compared with that in the adjacent tissues. The positive rates of uPA and uPAR expressed the tissues were 33.33%and 50.00%in G1 grade; 88.47%and 9 6.15%in G3 grade; 37.50%and 50.00%in Ta-T1 tissues; 100.0%and 100.0%in T4 tissues, respectively. The positive rates of uPA and uPAR expression in tumor ti ssues with higher grade and stage were obviously increased (P< 0.05); meanwhile, there were close correlation between uPA and uPAR (rs=0.979). CONCLUSION: The c o-expression of uPA and uPAR was one of the characteri-stics of urinary transi tional cell carcinoma and significantly correlated with tumor stage and grade.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
2004年第6期704-706,共3页
Chinese Journal of Cancer
关键词
膀胱
肾盂
输尿管
移行细胞癌
尿激酶型纤溶酶原激活物
Bladder
Ureter
Pelvic
Transitional cell carcinoma
Urokinase-typ e plasminogen activator (uPA)